Market closedNon-fractional

Pliant Therapeutics/PLRX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Pliant Therapeutics

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Ticker

PLRX

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

South San Francisco, United States

Employees

158

PLRX Metrics

BasicAdvanced
$638M
Market cap
-
P/E ratio
-$2.86
EPS
1.19
Beta
-
Dividend rate
$638M
1.19
16.12
15.949
12.321
12.497
-138.79%
-21.71%
-34.17%
2,549.398
1.47
1.47
-5.33
-97.46%
1.16%
-74.55%
4.10%

What the Analysts think about PLRX

Analyst Ratings

Majority rating from 14 analysts.
Buy

PLRX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$47M
14.11%
Profit margin
0.00%
NaN%

PLRX Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 1.10%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.70
-$0.70
-$0.69
-$0.78
-
Expected
-$0.71
-$0.78
-$0.81
-$0.77
-$0.85
Surprise
-1.87%
-9.68%
-15.22%
1.10%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Pliant Therapeutics stock?

Pliant Therapeutics (PLRX) has a market cap of $638M as of July 05, 2024.

What is the P/E ratio for Pliant Therapeutics stock?

The price to earnings (P/E) ratio for Pliant Therapeutics (PLRX) stock is 0 as of July 05, 2024.

Does Pliant Therapeutics stock pay dividends?

No, Pliant Therapeutics (PLRX) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Pliant Therapeutics dividend payment date?

Pliant Therapeutics (PLRX) stock does not pay dividends to its shareholders.

What is the beta indicator for Pliant Therapeutics?

Pliant Therapeutics (PLRX) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Pliant Therapeutics stock

Buy or sell Pliant Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing